Literature DB >> 18726139

Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements.

Werner J Schmidt1, Heike Lebsanft, Manfred Heindl, Manfred Gerlach, Edna Gruenblatt, Peter Riederer, Andreas Mayerhofer, Dieter K A Scheller.   

Abstract

Sustained drug delivery providing continuous dopaminergic stimulation is thought to prevent or delay the induction of motor complications (dyskinesia) in Parkinson's disease, whereas pulsatile administration is supposed to promote them. This study investigated the inducibility of sensitization and abnormal involuntary movements (AIMs), comparing continuous and pulsatile administration of rotigotine with pulsatile administration of 3,4-dihydroxy-L-phenylalanine (L-DOPA) for reference. Rats were unilaterally lesioned with 6 hydroxydopamine (6-OHDA). For pulsatile administration, L-DOPA-methylester (10 mg/kg L-DOPA i.p.) or rotigotine (1 mg/kg i.p.) were administered once or twice daily. For continuous administration, a slow release formulation of rotigotine was injected s.c. at a dose of 1 mg/kg every 48 h (experiment I) or every 24 h (experiment II). Pulsatile administration of rotigotine and L-DOPA caused contraversive rotations increasing progressively upon each successive treatment. AIMs started to occur after the second administration of L-DOPA but hardly after pulsatile rotigotine. Continuous rotigotine increased rotations, which reached a plateau after the second administration. No AIMs were observed under continuous administration. The continuous administration of rotigotine did not induce sensitization or AIMs, suggesting that continuous stimulation of dopaminergic receptors by rotigotine has no propensity to induce dyskinesia in this experimental model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726139     DOI: 10.1007/s00702-008-0102-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  36 in total

1.  Positive and negative interactions in the behavioural expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming.

Authors:  M Morelli; S Fenu; A Cozzolino; G Di Chiara
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

Review 2.  Animal models of Parkinson's disease in rodents induced by toxins: an update.

Authors:  E C Hirsch; G Höglinger; E Rousselet; T Breidert; K Parain; J Feger; M Ruberg; A Prigent; C Cohen-Salmon; J M Launay
Journal:  J Neural Transm Suppl       Date:  2003

Review 3.  Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.

Authors:  T N Chase; T M Engber; M M Mouradian
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

4.  Antidepressant properties of rotigotine in experimental models of depression.

Authors:  Valerie Bertaina-Anglade; Christophe Drieu La Rochelle; Dieter K A Scheller
Journal:  Eur J Pharmacol       Date:  2006-07-22       Impact factor: 4.432

5.  Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.

Authors:  J Kehr; X-J Hu; M Goiny; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2007-04-16       Impact factor: 3.575

6.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Authors:  M Lundblad; M Andersson; C Winkler; D Kirik; N Wierup; M Angela Cenci
Journal:  Eur J Neurosci       Date:  2002-01       Impact factor: 3.386

Review 7.  The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.

Authors:  R K Schwarting; J P Huston
Journal:  Prog Neurobiol       Date:  1996-10       Impact factor: 11.685

8.  Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Authors:  C S Lee; M A Cenci; M Schulzer; A Björklund
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

Review 9.  Preventing levodopa-induced dyskinesias.

Authors:  C W Olanow; J A Obeso
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

10.  The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.

Authors:  M Alam; A Mayerhofer; W J Schmidt
Journal:  Behav Brain Res       Date:  2004-05-05       Impact factor: 3.332

View more
  11 in total

1.  Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.

Authors:  E Grünblatt; W J Schmidt; D K A Scheller; P Riederer; M Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

Review 2.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 3.  Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

4.  Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.

Authors:  Willi Cawello; Andreas Fichtner; Hilmar Boekens; Marina Braun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-09-20       Impact factor: 2.441

5.  Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.

Authors:  Aiping Wang; Lexi Wang; Kaoxiang Sun; Wanhui Liu; Chunjie Sha; Youxin Li
Journal:  Pharm Res       Date:  2012-05-02       Impact factor: 4.200

Review 6.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 7.  Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.

Authors:  Qing Lv; Baorong Zhang
Journal:  Neurosci Bull       Date:  2013-03-20       Impact factor: 5.203

Review 8.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 9.  An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.

Authors:  Jan-Peer Elshoff; Willi Cawello; Jens-Otto Andreas; Francois-Xavier Mathy; Marina Braun
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 10.  Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Authors:  Jean-François Daneault; Benoit Carignan; Abbas F Sadikot; Michel Panisset; Christian Duval
Journal:  BMC Med       Date:  2013-03-20       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.